Direct fibrogenic effects of aldosterone on normotensive kidney: An effect modified by 11β-HSD activity

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 5, 2010, Pages

  Brem, Andrew S ^a   Morris, David J ^b   Ge, Yan ^a   Dworkin, Lance ^a   Tolbert, Evelyn ^a   Gong, Rujun ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Fibrosis; Glucocorticoids; Kidney; Mineralocorticoids; Renal epithelia

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ALDOSTERONE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTERONE; DEHYDROCORTICOSTERONE; FIBRONECTIN; GLUCOCORTICOID RECEPTOR ANTAGONIST; MIFEPRISTONE; RU 318; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROGENESIS; GENE OVEREXPRESSION; IN VIVO STUDY; KIDNEY; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NONHUMAN; NORMOTENSIVE KIDNEY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 77951519956     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00532.2009     Document Type: Article

References (45)

1. Alberti KGMM, Sharp GWG. Identification of four types of steroid by their interaction with mineralocorticoid receptors in the toad bladder. J Endocrinol 48: 563-574, 1970.
2. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314, 2005. (Pubitemid 46187550)
3. Artunc F, Amann K, Nasir O, Friedrich B, Sandulache D, Jahovic N, Risler T, Vallon V, Wulff P, Kuhl D, Lang F. Blunted DOCA/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1. J Mol Med 84: 737-746, 2006. (Pubitemid 44328065)
4. Ayachi SE, Paulmyer-Lacroix O, Verdier M, Alessi MC, Dutour A, Grino M. 11beta-Hydroxysteroid dehydrogenase type 1-driven cortisone reactivation regulates plasminogen activator inhibitor type 1 in adipose tissue of obese women. J Thromb Haemost 4: 621-627, 2006.
5. Barger AC, Berlin RD, Tulenko JF. Infusion of aldosterone, 9-alpha-fluorohydrocortisone, and antidiuretic hormone into the renal artery of normal and adrenalectomized unanesthetized dogs: effect on electrolyte and water excretion. Endocrinology 62: 804-815, 1958.
6. Brem AS, Bina B, Matheson KL, Barnes JL, Morris DJ. Developmental changes in rat renal 11 beta-hydroxysteroid dehydrogenase. Kidney Int 45: 679-683, 1994. (Pubitemid 24094478)
7. Brem AS, Bina RB, Fitzpatrick C, King T, Tang SS, Ingelfinger JR. Glucocorticoid metabolism in proximal tubules modulates angiotensin II-induced electrolyte transport. Proc Soc Exp Biol Med 221: 111-117, 1999. (Pubitemid 129772393)
8. Brem AS, Bina RB, King T, Chobanian MC, Morris DJ. Influence of dietary sodium on the renal isoforms of 11 beta-hydroxysteroid dehydrogenase. Proc Soc Exp Biol Med 214: 340-345, 1997. (Pubitemid 27212858)
9. Brem AS, Matheson KL, Barnes JL, Morris DJ. 11-Dehydrocorticosterone, a glucocorticoid metabolite, inhibits aldosterone action in toad bladder. Am J Physiol Renal Fluid Electrolyte Physiol 261: F873-F879, 1991.
10. Brown NJ. Salt in the wound. J Am Soc Nephrol 20: 5-6, 2009.
11. Eddy AA. Can renal fibrosis be reversed? Pediatr Nephrol 20: 1369-1375, 2005.
12. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209-F220, 2002.
13. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2: 986-989, 1988.
14. Farman N, Kusch M, Edelman IS. Aldosterone receptor occupancy and sodium transport in the urinary bladder of Bufo marinus. Am J Physiol Cell Physiol 235: C90-C96, 1978. (Pubitemid 9165878)
15. Funder JW, Feldman D, Edelman IS. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 92: 994-1004, 1973.
16. Gong R, Ge Y, Chen S, Liang E, Esparza A, Sabo E, Yango A, Gohh R, Rifai A, Dworkin LD. Glycogen synthase kinase 3beta: a novel marker and modulator of inflammatory injury in chronic renal allograft disease. Am J Transplant 8: 1852-1863, 2008.
17. Gong R, Latif S, Morris DJ, Brem AS. Colocalization of glucocorticoid metabolizing and prostaglandin synthesizing enzymes in rat kidney and liver. Life Sci 83: 725-731, 2008.
18. Gong R, Morris DJ, Brem AS. Human renal 11beta-hydroxysteroid dehydrogenase 1 functions and colocalizes with COX-2. Life Sci 82: 631-637, 2008.
19. Gong R, Morris DJ, Brem AS. Variable expression of 11beta Hydroxysteroid dehydrogenase (11β-HSD) isoforms in vascular endothelial cells. Steroids 73: 1187-1196, 2008.
20. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J Am Soc Nephrol 17: 2464-2473, 2006. (Pubitemid 44300962)
21. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 14: 3047-3060, 2003. (Pubitemid 37509283)
22. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996. (Pubitemid 26293326)
23. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006.
24. Ikeda H, Tsuruya K, Toyonaga J, Masutani K, Hayashida H, Hirakata H, Iida M. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 75: 147-155, 2009.
25. Ingelfinger JR. Forestalling fibrosis. N Engl J Med 349: 2265-2266, 2003.
26. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 286: F1059-F1062, 2004.
27. Keira SM, Ferreira LM, Gragnani A, Duarte ID, Barbosa J. Experimental model for collagen estimation in cell culture. Acta Cir Bras 19: 17-22, 2004.
28. Kramer AB, van der Meulen EF, Hamming I, van Goor H, Navis G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 71: 417-424, 2007.
29. Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, Vinciguerra M, Martin PY, Feraille E. Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol 20: 131-144, 2009.
30. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44: 1301-1307, 2004.
31. Morris DJ, Berek JS, Davis RP. The physiological response to aldosterone in adrenalectomized and intact rats and its sex dependence. Endocrinology 92: 989-993, 1973.
32. Morris DJ, Souness GW, Brem AS, Oblin ME. Interactions of mineralocorticoids and glucocorticoids in epithelial target tissues. Kidney Int 57: 1370-1373, 2000.
33. Odermatt A, Arnold P, Frey FJ. The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J Biol Chem 276: 28484-28492, 2001.
34. Okada H, Kikuta T, Inoue T, Kanno Y, Ban S, Sugaya T, Takigawa M, Suzuki H. Dexamethasone induces connective tissue growth factor expression in renal tubular epithelial cells in a mouse strain-specific manner. Am J Pathol 168: 737-747, 2006.
35. Porter GA, Edelman IS. The action of aldosterone and related corticosteroids on sodium transport across the toad bladder. J Clin Invest 43: 611-620, 1964.
36. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19: 1459-1462, 2008.
37. Reungjui S, Hu H, Mu W, Roncal CA, Croker BP, Patel JM, Nakagawa T, Srinivas T, Byer K, Simoni J, Wesson D, Sitprija V, Johnson RJ. Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int 72: 1483-1492, 2007.
38. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000.
39. Ross EJ. Modification of the effects of aldosterone on electrolyte excretion in man by simultaneous administration of corticosterone and hydrocortisone. Relevance to Conn's syndrome. J Clin Endocrinol Metab 20: 229-237, 1960.
40. Stanton BA. Role of adrenal hormones in regulating distal nephron structure and ion transport. Fed Proc 44: 2717-2722, 1985.
41. Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, Hirata Y, Sasaki S. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol 19: 298-309, 2008.
42. Tullberg-Reinert H, Jundt G. In situ measurement of collagen synthesis by human bone cells with a sirius red-based colorimetric microassay: effects of transforming growth factor beta2 and ascorbic acid 2-phosphate. Histochem Cell Biol 112: 271-276, 1999.
43. Uete T, Venning EH. The effect of cortisone, hydrocortisone, and 9-alpha-fluoro-16-alpha-hydroxy-delta-hydrocortisone on the action of desoxycorticosterone and aldosterone with respect to electrolyte excretion. Endocrinology 67: 62-69, 1960.
44. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919, 2006.
45. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 269: E657-E662, 1995.